Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;29(31):2400459.
doi: 10.2807/1560-7917.ES.2024.29.31.2400459.

Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024

Carla Rodrigues  1   2   3 , Valérie Bouchez  1   2   3 , Anaïs Soares  4 , Sabine Trombert-Paolantoni  5 , Fatima Aït El Belghiti  6 , Jérémie F Cohen  7   8 , Nathalie Armatys  2   3 , Annie Landier  2   3 , Thomas Blanchot  4 , Marie Hervo  4 ; REMICOQ study group  9 ; Julie Toubiana  10   8   2   3 , Sylvain Brisse  10   2   3
Collaborators, Affiliations

Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024

Carla Rodrigues et al. Euro Surveill. 2024 Aug.

Abstract

As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.

Keywords: Bordetella pertussis; FIM2 fimbriae; macrolide resistance; pertactin production; post-covid-19 resurgence.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Time series analysis of positive qPCR tests targeting IS481, France, 2012–2024
Figure 2
Figure 2
Characteristics of Bordetella pertussis isolates from France, June 2023–April 2024 (n = 67) vs 2016–2020
See this image and copyright information in PMC

References

    1. Machado MB, Passos SD. Severe pertussis in childhood: update and controversy - systematic review. Rev Paul Pediatr. 2019;37(3):351-62. 10.1590/1984-0462/;2019;37;3;00006 - DOI - PMC - PubMed
    1. Matczak S, Levy C, Fortas C, Cohen JF, Béchet S, Aït El Belghiti F, et al. Association between the COVID-19 pandemic and pertussis derived from multiple nationwide data sources, France, 2013 to 2020. Euro Surveill. 2022;27(25):2100933. 10.2807/1560-7917.ES.2022.27.25.2100933 - DOI - PMC - PubMed
    1. Tubiana S, Belchior E, Guillot S, Guiso N, Lévy-Bruhl D, Renacoq Participants . Monitoring the impact of vaccination on pertussis in infants using an active hospital-based pediatric surveillance network: results from 17 years’ experience, 1996-2012, France. Pediatr Infect Dis J. 2015;34(8):814-20. 10.1097/INF.0000000000000739 - DOI - PubMed
    1. Bouchez V, Guillot S, Landier A, Armatys N, Matczak S, Toubiana J, et al. Evolution of Bordetella pertussis over a 23-year period in France, 1996 to 2018. Euro Surveill. 2021;26(37):2001213. 10.2807/1560-7917.ES.2021.26.37.2001213 - DOI - PMC - PubMed
    1. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine. 2009;27(43):6034-41. 10.1016/j.vaccine.2009.07.074 - DOI - PubMed

MeSH terms

LinkOut - more resources